Examine the strategies community research sites can use to secure trial opportunities, from adopting AI-enabled workflows to ...

In today’s ACT Brief, we examine how community research sites can stay competitive under rising efficiency pressures, why ...

The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

Identifying copyright holders and response times are major challenges in COA licensing, causing delays in clinical trials. Clear documentation of copyright ownership and standardized response times ...

In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...

Explore how sponsors can recalibrate efficiency efforts to avoid overconcentrating trials at familiar sites and instead ...

Unpack how rising competition for the same high-profile sites is slowing startup and enrollment—and what sponsors must change ...

Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

In today’s ACT Brief, we hear how sponsors may redefine efficiency to protect patient access in 2026, review Verana Health’s ...

In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...

In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...